India’s Cipla Partially Exits Desano Of China; Redeploys Funds Into Biosimilars, APIs
This article was originally published in PharmAsia News
The Indian drug maker has embarked on a new China strategy that includes biosimilars.
You may also be interested in...
India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.